Publications by authors named "V C Vaz"
Article Synopsis
- Approximately 10% of lung adenocarcinomas (LUAD) have mucinous histology (LUADMuc), which is linked to a lighter/absent smoking history and a higher prevalence of KRAS mutations compared to LUAD without this histology (LUADnon-muc).
- A study analyzed features and treatment outcomes of LUADMuc and LUADnon-muc patients, revealing LUADMuc patients had less aggressive disease characteristics and a poorer response to current therapies, especially immunotherapy.
- Overall, LUADMuc showed lower objective response rates, shorter progression-free and overall survival compared to LUADnon-muc, highlighting a need for more effective treatment strategies for this subgroup.
Research aimed at investigating the ideal plant arrangement system of common beans under intercropping with castor hybrids is necessary, as intercropping is a common practice in Brazil, and this practice affects the morphophysiological behavior of both crops. The objective of this study was to evaluate the consociation systems of common bean plants with small-sized castor hybrid, in three agricultural years, in the edaphoclimatic conditions of the Cerrado of Goiás, Brazil. In the three experiments, the randomized block design with four repetitions was used, involving the combination of five simultaneous sowing systems: beans sown on the castor row, on the inter-row, on the row + inter-row and beans and castor in monocropping.
View Article and Find Full Text PDFCrizotinib successfully overcomes MET amplification in ROS1-rearranged NSCLC after entrectinib failure.
View Article and Find Full Text PDFBackground: Programmed death receptor ligand 1 (PD-L1) tumor proportion score (TPS) and tumor mutational burden (TMB) are key predictive biomarkers for immune checkpoint inhibitor (ICI) efficacy in non-small-cell lung cancer (NSCLC). Data on their variation across multiple samples are limited.
Patients And Methods: Patients with NSCLC and multiple PD-L1 TPS and/or TMB assessments were included.
Article Synopsis
- Activating point mutations in the MET tyrosine kinase domain are identified as oncogenic drivers in various cancers, occurring in about 0.5% of cases, particularly in certain papillary renal cell carcinomas.
- Specific mutations at positions H1094, L1195, F1200, D1228, Y1230, and M1250 were labeled as oncogenic or likely oncogenic based on genetic profiling.
- Preclinical models and patient responses indicate that these mutations may enhance sensitivity to MET inhibitors, highlighting the potential for targeted precision treatments in oncology.